AYTUライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:05):

Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally...

Stats
本日の出来高	2 675.00
平均出来高	20 935.00
時価総額	16.30M
EPS	$0 ( 2024-02-14 )
次の収益日	( $-0.640 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.730
ATR14	$0.0310 (1.06%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-31	Pyszczymuka Greg	Buy	208	Common Shares
2024-03-31	Pyszczymuka Greg	Sell	208	Restricted Stock Units
2023-12-31	Pyszczymuka Greg	Buy	209	Common Shares
2023-12-31	Pyszczymuka Greg	Sell	209	Restricted Stock Units
2023-09-30	Pyszczymuka Greg	Buy	208	Common Shares

INSIDER POWER
30.98
Last 94 transactions
Buy: 33 552 785 \| Sell: 39 056 468

Aytu BioScience Inc 相関

10 最も正の相関
REYN	0.959
SRNGW	0.954
IBRX	0.951
VWE	0.949
HCAQ	0.948
JAGX	0.946
CHKEL	0.945
PROC	0.943
MAGS	0.942
LGMK	0.941

10 最も負の相関
SMAP	-0.957
OVLY	-0.955
VAQC	-0.953
IPVIU	-0.948
SY	-0.948
GENQ	-0.948
ATEC	-0.946
HPLTU	-0.944
SJ	-0.943
IGTA	-0.943

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Aytu BioScience Inc 財務諸表

Annual	2023
収益:	$107.40M
総利益:	$66.63M (62.04 %)
EPS:	$-5.11

FY	2023
収益:	$107.40M
総利益:	$66.63M (62.04 %)
EPS:	$-5.11

FY	2022
収益:	$96.67M
総利益:	$52.28M (54.08 %)
EPS:	$-1 499.10

FY	2021
収益:	$65.63M
総利益:	$29.20M (44.49 %)
EPS:	$-0.174

Financial Reports:

No articles found.

Aytu BioScience Inc

Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from 6 years and older; Cotempla XR-ODT for the treatment of ADHD in patients from 6 to 17 years old; and Adzenys ER, an oral suspension for the treatment of ADHD in patients from 6 years and older. It also provides Karbinal ER, a carbinoxamine oral suspension for the treatment of seasonal and perennial allergies; Poly-Vi-Flor and Tri-Vi-Flor prescription supplements for infants and children for the treatment of fluoride deficiency; Tuzistra XR, a prescription antitussive consisting of codeine polistirex and chlorpheniramine polistirex in an oral suspension; and ZolpiMist, an oral spray for the treatment of insomnia. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. was incorporated in 2015 and is headquartered in Englewood, Colorado.